No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
IONS240517C40000
- 0.18
- +0.03+20.00%
15min DelayClose May 15 15:59 ET
0.18High0.10Low
0.10Open0.15Pre Close3 Volume136 Open Interest40.00Strike Price46.00Turnover42.91%IV2.47%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.18Time Value100Contract SizeAmericanOptions Type0.2591Delta0.2771Gamma217.83Leverage Ratio-0.1170Theta0.0005Rho56.44Eff Leverage0.0088Vega
Intraday
- 5D
- 1D
News
Express News | Biogen Inc: Development of Biib105, Will Be Discontinued Based on Data From Phase 1/2 Alspire Study
Express News | Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
Express News | Ionis Pharmaceuticals Inc: Ion582 Was Safe and Well Tolerated at All Dose Levels
Express News | Ionis Pharmaceuticals Inc: Ion582 Demonstrated Consistent Improvements Across Multiple Functional Domains in Angelman Syndrome Patients
Express News | Ionis Pharmaceuticals Inc: Ionis Plans to Move Ion582 Into Pivotal Trial
Express News | Ionis Announces Positive Topline Results From Phase 1/2a Trial of Ion582 for Angelman Syndrome
Comments
$Ionis Pharmaceuticals(IONS.US$
NEWS
“Ionis Pharmaceuticals announces positive Phase 3 results for olezarsen in treating familial chylomicronemia syndrome, showing significant reduction in triglycerides and acute pancreatitis events, potentially offering a breakthrough treatment option.
Results demonstrate olezarsen may represent a novel treatment option for this rare, life-threatening disease, for which there are no approved treatments in the U.S.”
NEWS
“Ionis Pharmaceuticals announces positive Phase 3 results for olezarsen in treating familial chylomicronemia syndrome, showing significant reduction in triglycerides and acute pancreatitis events, potentially offering a breakthrough treatment option.
Results demonstrate olezarsen may represent a novel treatment option for this rare, life-threatening disease, for which there are no approved treatments in the U.S.”
1
Ionis Pharmaceuticals' liabilities need constant monitoring despite its net cash indicating manageable debt. Future earnings are key for a healthy balance sheet. Its revenue growth suggests a path to profitability, but lack of profitability and cash burn make it risky.
2
Kyle Jenne's appointment, with his vast experience and previous tenure at Ionis, is expected to boost the company's commercial organization during a key growth period and product launches. His leadership is anticipated to help Ionis maximize the potential of its innovative medicines to reach patients and healthcare providers.
Recent insider selling at Ionis Pharmaceuticals may indicate insiders believe shares are overpriced. The absence of insider buying and history of sales could caution potential investors.
Investors might be overlooking potential risks as Ionis boasts a similar P/S ratio to the Biotech industry, despite weaker revenue outlook. Modest revenue growth could potentially put a downward pressure on the stock and put investments at risk.
Read more